Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study

Mathias J Rummel, Tae Min Kim, Franco Aversa, MD, Wolfram Brugger, MDPhD, Enrico Capochiani, Caterina Plenteda, Francesca Re, Peter Task, Christine McIntyre, Oliver Meier, Stuart Osborne, Rodney Smith, Andrew Grigg, MBBS FRACP FRCPA

Blood (2017) 130 (Supplement 1): 2834.

https://doi.org/10.1182/blood.V130.Suppl_1.2834.2834

Published: 2017

Journal Articles

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, Lisa Carne, RN, David Ross, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 1503.

https://doi.org/10.1182/blood.V122.21.1503.1503

Published: 2013

Journal Articles

Autologous Hematopoietic Cell Transplantation (HCT) Is Superior To Allogeneic Transplantation For Acute Promyelocytic Leukemia In Second Complete Remission (CR2)

Jennifer L. Holter-Chakrabarty, MD, Morel Rubinger, MD, Andrew Grigg, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, George Selby, MD, Jacob M Rowe, MD, Jennifer Le Rademacher, PhD, Hailin Wang, MS, Daniel J. Weisdorf, MD, Martin S Tallman, MD

Blood (2013) 122 (21): 418.

https://doi.org/10.1182/blood.V122.21.418.418

Published: 2013

Journal Articles

Early Molecular Response to Imatinib in CP-CML Patients: The Significance of Early Dose Intensity and OCT-1 Activity in Responders and Efficacy of Dose Escalation and Switch to Nilotinib in Non-Responders

Deborah L. White, PhD, FFSc(RCPA), Verity A Saunders, BScHons, David T Yeung, BSc, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS

Blood (2012) 120 (21): 693.

https://doi.org/10.1182/blood.V120.21.693.693

Published: 2012

Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA

Blood (2012) 120 (21): 3686.

https://doi.org/10.1182/blood.V120.21.3686.3686

Published: 2012

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA

Blood (2011) 118 (21): 451.

https://doi.org/10.1182/blood.V118.21.451.451

Published: 2011

Journal Articles

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

Huyen Tran, MBBS, MSc, FRACP, FRCPA, Jamie P Nourse, PhD, Rod Lea, PhD, Timothy A. Brighton, FRCPA, FRACP, MB, BS, MS, Andrew Grigg, MBBS, FRACP, FRCPA, Simon McRae, BMedSc, MBBS, FRACP, FRCPA, Daniel Thurley, MA, MB, BCHIR, Dep. pharm. med, MRCP, FFPM, Maher Gandhi, PhD, FRACP, FRCPath, FRCP, John Catalano, MBBS FRACP FRCPA

Blood (2011) 118 (21): 1157.

https://doi.org/10.1182/blood.V118.21.1157.1157

Published: 2011

Journal Articles

A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients with Haemoglobinopathies, Myelodysplastic Syndromes or Other Anaemias Treated with Deferasirox (the MILE study CICL670AAU01) – Results of An Interim Analysis At a Planned Sample Size Reassessment,

P. Joy Ho, MBBS, FRACP, FRCPA, DPhil, Lay Tay, MBBS, FRCPA, Juliana Teo, MBBS, FRCPA, FRACP, Paula Marlton, MBBS, Andrew Grigg, MBBS, FRACP, FRCPA, Tim St. Pierre, PhD, Greg Brown, Fellow SMRT, Othon L Gervasio, DDS, MS, PhD, Donald K Bowden, MD

Blood (2011) 118 (21): 3181.

https://doi.org/10.1182/blood.V118.21.3181.3181

Published: 2011

Journal Articles

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Deborah L. White, PhD. FFSc(RCPA), Verity A Saunders, BScHons, Amity Frede, BScHons, Kelvin GrootObbink, BScHons, Cassandra Slader, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P Hughes, MD, MBBS

Blood (2011) 118 (21): 1690.

https://doi.org/10.1182/blood.V118.21.1690.1690

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Peter T. Tan, MBBS, Kate Reed, BSc, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Othon L Gervasio, DDS, MS, PhD, Ivo J. Winiger, MD, Dirk Hönemann, MD, Andrew H Wei, MBBS, PhD, Andrew Spencer, MD

Blood (2011) 118 (21): 1529.

https://doi.org/10.1182/blood.V118.21.1529.1529

Published: 2011

Journal Articles

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD, Susan Branford, PhD, Lauren Haswell, MSci, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K. Hiwase, MBBS, PhD, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K. Arthur, MBBS, Yiu Lam Kwan, MBBS, FRACP, FRCPA, Cecily J. Forsyth, FRACP, FRCPA, David M. Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2010) 116 (21): 209.

https://doi.org/10.1182/blood.V116.21.209.209

Published: 2010

Journal Articles

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Deborah L. White, PhD, Verity Saunders, Amity Frede, Kelvin GrootObbink, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 356.

https://doi.org/10.1182/blood.V116.21.356.356

Published: 2010

Journal Articles

Imatinib PK: Observations From the TIDEL II Study

Deborah L. White, PhD, Verity Saunders, Menelaou Andrew, Allan Rofe, PhD, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 2288.

https://doi.org/10.1182/blood.V116.21.2288.2288

Published: 2010

Journal Articles

Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.

John Francis Seymour, MBBS FRACP, Andrew Grigg, MBBS FRACP, John Reynolds, Jane Matthews, Anthony P. Schwarer, MBBS FRACP, Richard Herrmann, MBBS FRACP, Kerry McDonald Taylor, MBBS FRACP, Mark S. Hertzberg, MBBS FRACP, Anthony Mills, MBBS FRACP, Nancy Guzzo-Pernell, Michael Copeman, MBBS FRACP, Kevin Lynch, MBBS, Timothy Hughes, MBBS FRACP

Blood (2004) 104 (11): 1020.

https://doi.org/10.1182/blood.V104.11.1020.1020

Published: 2004

Journal Articles

Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype.

Duncan Carradice, MBBS, Peter Shuttleworth, RN, Jeffrey Szer, MBBS FRACP, Andrew Roberts, MBBS PhD FRACP FRCP, Andrew Grigg, MBBS FRACP FRCPA

Blood (2004) 104 (11): 2262.

https://doi.org/10.1182/blood.V104.11.2262.2262

Published: 2004

NARROW

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

Autologous Hematopoietic Cell Transplantation (HCT) Is Superior To Allogeneic Transplantation For Acute Promyelocytic Leukemia In Second Complete Remission (CR2)

Early Molecular Response to Imatinib in CP-CML Patients: The Significance of Early Dose Intensity and OCT-1 Activity in Responders and Efficacy of Dose Escalation and Switch to Nilotinib in Non-Responders

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms

A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients with Haemoglobinopathies, Myelodysplastic Syndromes or Other Anaemias Treated with Deferasirox (the MILE study CICL670AAU01) – Results of An Interim Analysis At a Planned Sample Size Reassessment,

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Imatinib PK: Observations From the TIDEL II Study

Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML.

Tissue Iron Overload Is Common Post Transplantation (Allo BMT) and Is Associated with Red Cell Transfusion Load and HFE Genotype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only